Hepatitis B Virus Nucleocapsid Assembly
Journal of Molecular Biology · 2025
DOI: 10.1016/j.jmb.2025.169182 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Molecular Biology, 2025. Verfasst von Xupeng Hong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA. Electronic address: xhong@rockefeller.edu. Hauptthemen laut MEDLINE: Hepatitis B virus, Nucleocapsid, Virus Assembly. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, GlaxoSmithKline, National Institutes of Health National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Hepatitis B virus (HBV), the prototypical member of the Hepadnaviridae family, is a DNA virus that replicates its genome through reverse transcription of a pregenomic RNA (pgRNA) precursor. The selective packaging of pgRNA and viral polymerase (Pol) into assembling capsids formed by the viral core protein-a process known as nucleocapsid assembly-is an essential step in the HBV lifecycle. Advances in cellular and cell-free systems have provided significant insights into the mechanisms underlying capsid assembly, Pol binding to pgRNA, Pol-pgRNA packaging, and initiation of genome replication. However, the absence of a cell-free system capable of reconstituting selective HBV Pol-pgRNA packaging into fully assembled capsids leaves fundamental questions about nucleocapsid assembly unanswered. This review summarizes the current knowledge of HBV nucleocapsid assembly, focusing on the interplay between Pol-pgRNA interactions, capsid formation, and regulation by host factors. It also highlights the contribution of cellular and cell-free systems to these discoveries and underscores the need for new approaches that reconstitute the complete HBV nucleocapsid assembly process. With the growing interest in developing nucleocapsid assembly inhibitors, some of which are currently in clinical trials, targeting Pol-pgRNA interactions and nucleocapsid assembly represents a promising therapeutic strategy for curing chronic hepatitis B.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA. Electronic address: xhong@rockefeller.edu.
- Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Förderung
- NIAID NIH HHS
- GlaxoSmithKline
- National Institutes of Health National Institute of Allergy and Infectious Diseases
- Vir Biotechnology
- National Institutes of Health
- Rockefeller University
- Stavros Niarchos Foundation
Zitieren
APA
Hong, X., Schneider, W. M., & Rice, C. M. (2025). Hepatitis B Virus Nucleocapsid Assembly. Journal of Molecular Biology. https://doi.org/10.1016/j.jmb.2025.169182
Vancouver
Hong X, Schneider WM, Rice CM. Hepatitis B Virus Nucleocapsid Assembly. Journal of Molecular Biology. 2025. doi:10.1016/j.jmb.2025.169182
BibTeX
@article{Hong2025,
author = {Hong, Xupeng and Schneider, William M and Rice, Charles M},
title = {Hepatitis B Virus Nucleocapsid Assembly},
journal = {Journal of Molecular Biology},
year = {2025},
doi = {10.1016/j.jmb.2025.169182}
}
EUVIMED